Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic ReviewSMIELIAUSKAS, Fabrice; CHIEN, Chun-Ru; CHAN SHEN et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 7, pp 651-680, issn 1170-7690, 30 p.Article

Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010WISLØFF, Torbjørn; HAGEN, Gunhild; HAMIDI, Vida et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 4, pp 367-375, issn 1170-7690, 9 p.Article

Hospital-Based Health Technology Assessment: Developments to DateGAGNON, Marie-Pierre.PharmacoEconomics (Auckland). 2014, Vol 32, Num 9, pp 819-824, issn 1170-7690, 6 p.Article

Methods for Adjusting for Bias Due to Crossover in Oncology TrialsISHAK, K. Jack; PROSKOROVSKY, Irina; KORYTOWSKY, Beata et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 6, pp 533-546, issn 1170-7690, 14 p.Article

Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to ConsiderSTEVENSON, Matt D; SELBY, Peter L.PharmacoEconomics (Auckland). 2014, Vol 32, Num 8, pp 735-743, issn 1170-7690, 9 p.Article

The Better than Dead Method: Feasibility and Interpretation of a Valuation StudyVAN HOORN, R. A; DONDERS, A. R. T; OPPE, M et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 8, pp 789-799, issn 1170-7690, 11 p.Article

The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate CancerJAYASEKERA, J; ONUKWUGHA, E; BIKOV, K et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 2, pp 173-191, issn 1170-7690, 19 p.Article

The Value of a QALY: Individual Willingness to Pay for Health Gains Under RiskBOBINAC, Ana; VAN EXEL, Job; RUTTEN, Frans F. H et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 1, pp 75-86, issn 1170-7690, 12 p.Article

Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled TrialWILSON, Edward C. F; SHULGINA, Ludmila; CAHN, Anthony P et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 1, pp 87-99, issn 1170-7690, 13 p.Article

Ahead of Its Time? Reflecting on New Zealand's Pharmac Following Its 20th AnniversaryGAULD, Robin.PharmacoEconomics (Auckland). 2014, Vol 32, Num 10, pp 937-942, issn 1170-7690, 6 p.Article

Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic ModelsTAPPENDEN, Paul; CHILCOTT, James B.PharmacoEconomics (Auckland). 2014, Vol 32, Num 10, pp 967-979, issn 1170-7690, 13 p.Article

Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary SyndromeGIALAMA, Fotini; MILONI, Evangelia; MANIADAKIS, Nikos et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 11, pp 1063-1078, issn 1170-7690, 16 p.Article

Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best-Best Discrete Choice ExperimentGHIJBEN, Peter; LANCSAR, Emily; ZAVARSEK, Silva et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 11, pp 1115-1127, issn 1170-7690, 13 p.Article

Acknowledging Patient Heterogeneity in Economic Evaluation: A Systematic Literature ReviewGRUTTERS, Janneke P. C; SCULPHER, Mark; BRIGGS, Andrew H et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 2, pp 111-123, issn 1170-7690, 13 p.Article

Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary SyndromePARTHAN, Anju; LEAHY, Kevin J; O'SULLIVAN, Amy K et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 6, pp 519-531, issn 1170-7690, 13 p.Article

Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C PatientsBLAZQUEZ-PEREZ, Antonio; MIGUEL, Ramón San; MAR, Javier et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 10, pp 919-931, issn 1170-7690, 13 p.Article

Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical StudiesBRENNAN, Victoria K; DIXON, Simon.PharmacoEconomics (Auckland). 2013, Vol 31, Num 8, pp 677-691, issn 1170-7690, 15 p.Article

Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United StatesSIMPSON, Kit N; PEI, Pamela P; MÖLLER, Jörgen et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 5, pp 427-444, issn 1170-7690, 18 p.Article

Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et alVAN BAAL, Pieter; MELTZER, David; BROUWER, Werner et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 5, pp 369-373, issn 1170-7690, 5 p.Article

Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology AppraisalWADE, Ros; ROSE, Micah; NEILSON, Aileen Rae et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 10, pp 841-852, issn 1170-7690, 12 p.Article

A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV InfectionMAUSKOPF, Josephine.PharmacoEconomics (Auckland). 2013, Vol 31, Num 11, pp 1031-1050, issn 1170-7690, 20 p.Article

Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral AnticoagulantsKASMERIDIS, Charalampos; APOSTOLAKIS, Stavros; EHLERS, Lars et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 11, pp 971-980, issn 1170-7690, 10 p.Article

A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary DiseaseMENN, Petra; LEIDL, Reiner; HOLLE, Rolf et al.PharmacoEconomics (Auckland). 2012, Vol 30, Num 9, pp 825-840, issn 1170-7690, 16 p.Article

Costs Associated with Febrile Neutropenia in the USMICHELS, Shannon L; BARRON, Rich L; REYNOLDS, Matthew W et al.PharmacoEconomics (Auckland). 2012, Vol 30, Num 9, pp 809-823, issn 1170-7690, 15 p.Article

Dabigatran Etexilate: A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial FibrillationMCKEAGE, Kate.PharmacoEconomics (Auckland). 2012, Vol 30, Num 9, pp 841-855, issn 1170-7690, 15 p.Article